Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Completed
Bausch Health Americas, Inc.
Phase 4
2016-08-04
Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the
treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Completed
Valeant Pharmaceuticals International, Inc.
Phase 4
2016-08-04
Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the
treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish
Completed
University of Alabama at Birmingham
Phase 4
2015-09-01
This study will test how well efinaconazole solution (Jublia) works to treat toenail fungal
infections in patients who wear polish compared to those who do not.
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Completed
Western University of Health Sciences
Phase 3
2017-06-06
Onychomycosis, a common pathology of the toenails, is even more prevalent among diabetic
subjects. Nearly 26 million Americans suffer from diabetes, and approximately one-third of
subjects with diabetes have toenail onychomycosis. Numerous studies have addressed the
efficacy and safety of both topical and oral antifungal treatment options for onychomycosis
in diabetic subjects. However, no study to date has specifically addressed the efficacy and
safety of efinaconazole among diabetic subjects.
The objective of this noncomparative, uncontrolled study is to determine the efficacy of
topical efinaconazole 10% for toenail onychomycosis among subjects with diabetes mellitus.
Specific indicators to measure efficacy of treatment will be the mycological cure rate,
complete cure rate, and treatment success. Furthermore, an additional goal of the study is to
gain knowledge of safety in the setting of a cohort of diabetic subjects
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
